Blog
49 Articles
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
New NCCN Guidelines Stress Genetic Testing For All Pancreatic Cancer Patients
Genetics impact your treatment for pancreatic cancer. Dr. Sapna Syngal discusses the recommendation of genetic testing for all pancreatic cancer patients.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
Molecular Sequencing Leads to Customized Treatment
When Florida resident Doron Broman was diagnosed with stage IV pancreatic cancer, his decision to get treated in Boston gave him access a PARP inhibitor for maintenance.
Listen to Your Body
When Roxanne Waling discovered she had pancreatic cancer she underwent genetic testing. She found she was a BRCA2 carrier, which influenced her post-treatment decisions about her health.
Reimagining the Possible to Survive Stage IV Pancreatic Cancer
Marisa Harris was given a devastating diagnosis of stage IV pancreatic cancer. She tapped the power within herself, as well as chemotherapy, to become a long-term survivor.
Using the Energy Around Me to Help Me Heal
Judith Glaser’s genetic mutation influenced her chemotherapy and radiation treatments, supported by the healing energy of friends.
Tumor Genetics Research Brings Some Answers for Families at High Risk
Professor Gloria Peterson of the Mayo Clinic is working on tumor genetics to help make early detection of pancreatic cancer a reality.
A Clinical Trial Matches My Genetics
Steven Merlin learned that he carried the BRCA2 mutation after he developed pancreatic cancer. He researched and found a clinical trial for BRCA carriers.
A New Drug Combination to Control Advanced Pancreatic Cancer
A clinical trial for pancreatic cancer patients with the BRCA mutation tests the effectiveness of standard treatment plus a PARP inhibitor.
Exploring the Effectiveness of an Experimental Class of Drug
Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?
The Impact of BRCA Is Broader Than Breast and Ovarian Cancer
Rona Greenberg discusses the impact of BRCA2 on her family, and her search for the best clinical trial for her needs after her pancreatic cancer diagnosis.
Maintenance Chemotherapy Trial for Pancreatic Cancer Patients with the BRCA Mutation
A clinical trial for patients with BRCA mutations uses a PARP inhibitor as part of the maintenance chemotherapy experimental treatment.
Understanding a Family’s Risk for Pancreatic Cancer
A tumor registry studies the genetics of pancreatic cancer to determine risk factors for families.